Other Viruses Citation List: December 19 - January 1, 2015

Hepatitis C Virus

1. Mass Balance, Metabolite Profile, and in Vitro-in Vivo Comparison of Clearance Pathways of Deleobuvir, a Hepatitis C Virus Polymerase Inhibitor. Chen, L.Z., J.P. Sabo, E. Philip, L. Rowland, Y. Mao, B. Latli, D. Ramsden, D.A. Mandarino, and R.S. Sane. Antimicrobial Agents and Chemotherapy, 2015. 59(1): p. 25-37. PMID[25313217].

[PubMed]. OV_1219-010115.

2. Antiviral Activity of Virocidal Peptide Derived from NS5A Against Two Different HCV Genotypes: An in Vitro Study. El-Shenawy, R., A. Tabll, N.G. Bader El Din, Y. El Abd, M. Mashaly, C.A. Abdel Malak, R. Dawood, and M. El-Awady. Journal of Immunoassay & Immunochemistry, 2015. 36(1): p. 63-79. PMID[24606010].

[PubMed]. OV_1219-010115.

3. Inhibitory Effects of Pycnogenol(R) on Hepatitis C Virus Replication. Ezzikouri, S., T. Nishimura, M. Kohara, S. Benjelloun, Y. Kino, K. Inoue, A. Matsumori, and K. Tsukiyama-Kohara. Antiviral Research, 2015. 113: p. 93-102. PMID[25446333].

[PubMed]. OV_1219-010115.

4. In Vitro Antiviral Activity and Preclinical and Clinical Resistance Profile of Miravirsen, A Novel Anti-hepatitis C Virus Therapeutic Targeting the Human Factor miR-122. Ottosen, S., T.B. Parsley, L. Yang, K. Zeh, L.J. van Doorn, E. van der Veer, A.K. Raney, M.R. Hodges, and A.K. Patick. Antimicrobial Agents and Chemotherapy, 2015. 59(1): p. 599-608. PMID[25385103].

[PubMed]. OV_1219-010115.

5. Exploiting ChEMBL Database to Identify Indole Analogs as HCV Replication Inhibitors. Vrontaki, E., G. Melagraki, T. Mavromoustakos, and A. Afantitis. Methods, 2015. 71: p. 4-13. PMID[24680700].

[PubMed]. OV_1219-010115.

6. Computational Study on the Drug Resistance Mechanism of HCV NS5B RNA-dependent RNA Polymerase Mutants V494I, V494A, M426A, and M423T to Filibuvir. Wang, H., C. Guo, B.Z. Chen, and M. Ji. Antiviral Research, 2015. 113: p. 79-92. PMID[25449363].

[PubMed]. OV_1219-010115.

7. Macromolecular (Pro)drugs with Concurrent Direct Activity against the Hepatitis C Virus and Inflammation. Wohl, B.M., A.A. Smith, B.E. Jensen, and A.N. Zelikin. Journal of Controlled Release 2014. 196: p. 197-207. PMID[25451544].

[PubMed]. OV_1219-010115.

Feline Immunodeficiency Virus

8. Selective Interaction of Heparin with the Variable Region 3 Within Surface Glycoprotein of Laboratory-adapted Feline Immunodeficiency Virus. Hu, Q.Y., E. Fink, C.K. Grant, and J.H. Elder. PLoS One, 2014. 9(12): p. e115252. PMID[25521480].

[PubMed]. OV_1219-010115.

Human Cytomegalovirus

9. Ex Vivo Model of Congenital Cytomegalovirus Infection and New Combination Therapies. Morere, L., D. Andouard, F. Labrousse, F. Saade, C.A. Calliste, S. Cotin, Y. Aubard, W.D. Rawlinson, F. Esclaire, S. Hantz, M.C. Ploy, and S. Alain. Placenta, 2015. 36(1): p. 41-47. PMID[25479789].

[PubMed]. OV_1219-010115.

10. Statins Demonstrate a Broad Anti-cytomegalovirus Activity in Vitro in Ganciclovir-susceptible and Resistant Strains. Ponroy, N., A. Taveira, N.J. Mueller, and A.L. Millard. Journal of Medical Virology, 2015. 87(1): p. 141-153. PMID[24976258].

[PubMed]. OV_1219-010115.

11. Development of a High-content Screen for the Identification of Inhibitors Directed against the Early Steps of the Cytomegalovirus Infectious Cycle. T, J.G., T. Cohen, V. Redmann, Z. Lau, D. Felsenfeld, and D. Tortorella. Antiviral Research, 2015. 113: p. 49-61. PMID[25446405].

[PubMed]. OV_1219-010115.

Herpes Simplex Virus 2

12. Antiviral Activity of a Single-domain Antibody Immunotoxin Binding to Glycoprotein D of Herpes Simplex Virus 2. Geoghegan, E.M., H. Zhang, P.J. Desai, A. Biragyn, and R.B. Markham. Antimicrobial Agents and Chemotherapy, 2015. 59(1): p. 527-535. PMID[25385102].

[PubMed]. OV_1219-010115.

13. Fungal Metabolite Myriocin Promotes Human Herpes Simplex Virus-2 Infection. Wang, J., X. Guo, Z. Yang, R.X. Tan, X. Chen, and E. Li. Life Sciences, 2015. 120: p. 31-38. PMID[25447452].

[PubMed]. OV_1219-010115.

Citations from the ISI Web of Knowledge Listings for O.V.

14. Synthesis of Unnatural 3'-Phospha-2'-deoxyfuranose Nucleoside Analogues. Dayde, B., C. Pierra, G. Gosselin, D. Surleraux, A.T. Ilagouma, J.N. Volle, D. Virieux, and J.L. Pirat. Tetrahedron Letters, 2014. 55(46): p. 6328-6330. ISI[000345477200007].

[WOS]. OV_1219-010115.

15. Synthesis and anti-Hepatitis B Virus Activities of Heterocyclic Substituted Matijin-su Derivatives. Liang, G.P., Z.X. Hu, Q.C. Liu, Z.M. Huang, J.X. Zhang, G.Y. Liang, and B.X. Xu. Chemical Journal of Chinese Universities, 2014. 35(11): p. 2353-2359. ISI[000345540800012].

[WOS]. OV_1219-010115.

16. A Therapeutic anti-Hepatitis C Virus shmiRNA Integrated into the miR-122 Genomic Locus Mediates a Potent Anti-viral Response. Senis, E., S. Mockenhaupt, D. Rupp, R. Bartenschlager, and D. Grimm. Human Gene Therapy, 2014. 25(11): p. A51-A52. ISI[000344774700156].

[WOS]. OV_1219-010115.

17. UFLC/MS-IT-TOF Guided Isolation of anti-HBV Active Chlorogenic acid Analogues from Artemisia capillaris as a Traditional Chinese Herb for the Treatment of Hepatitis. Zhao, Y., C.A. Geng, Y.B. Ma, X.Y. Huang, H. Chen, T.W. Cao, K. He, H. Wang, X.M. Zhang, and J.J. Chen. Journal of Ethnopharmacology, 2014. 156: p. 147-154. ISI[000345734400019].

[WOS]. OV_1219-010115.